The startup develops novel antimicrobial compounds targeting multi-drug resistant gram-negative bacteria for use in pharmaceutical applications, medical devices, and material coatings. This technology enables healthcare professionals to effectively treat infections that are resistant to conventional antibiotics.
Funding
$570K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of multi-drug resistant gram-negative bacteria poses a significant threat to global health, rendering many conventional antibiotics ineffective. This resistance leads to increased morbidity, mortality, and healthcare costs, demanding novel antimicrobial solutions.
Solution
MetalloBio is developing a new class of antimicrobial compounds based on inorganic chemistry to combat multi-drug resistant bacteria. Their compounds, including Series 1 and Series 2, exhibit novel bactericidal modes of action, effectively killing bacteria through mechanisms distinct from existing antibiotics. Series 1 compounds are designed as candidate antibiotics for complicated infections, while Series 2 compounds form the basis of antibacterial coatings for medical devices. MetalloBio's compounds are fast-acting, demonstrate the ability to penetrate and disrupt biofilms, and show minimal propensity to elicit genetic resistance.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel antibiotic candidates, medical device manufacturers looking to incorporate antibacterial coatings, and healthcare providers treating patients with complicated, drug-resistant infections.
Features
- Broad-spectrum activity against Gram-negative and Gram-positive bacteria, including ESKAPE pathogens
- Novel bactericidal mechanisms of action, distinct from existing antibiotic classes
- Series 1 compounds (e.g., KLS-116) for treating complicated bacterial infections
- Series 2 compounds (e.g., KLS-219) for creating antibacterial coatings on medical devices
- Demonstrated efficacy in penetrating and disrupting biofilms, enhancing treatment of persistent infections
- Minimal development of genetic resistance, ensuring long-term effectiveness
- Thermostable compounds active across a wide pH range (pH3-pH10)
- Modular design allowing for the creation of numerous derivatives with targeted antimicrobial properties